Hemispherx BioPharma, Inc (NYSE:HEB) saw a large increase in short interest in the month of April. As of April 28th, there was short interest totalling 690,823 shares, an increase of 28.1% from the April 13th total of 539,159 shares. Based on an average daily volume of 545,602 shares, the short-interest ratio is presently 1.3 days. Currently, 2.8% of the company’s shares are sold short.
In other Hemispherx BioPharma news, CEO Thomas K. Equels bought 200,000 shares of the business’s stock in a transaction on Tuesday, April 11th. The shares were bought at an average cost of $0.50 per share, for a total transaction of $100,000.00. Following the transaction, the chief executive officer now owns 420,455 shares in the company, valued at approximately $210,227.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Thomas K. Equels bought 72,464 shares of the business’s stock in a transaction on Thursday, April 27th. The shares were acquired at an average price of $0.69 per share, for a total transaction of $50,000.16. Following the completion of the transaction, the chief executive officer now owns 492,919 shares in the company, valued at approximately $340,114.11. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 321,161 shares of company stock worth $176,448.
Hemispherx BioPharma (NYSE:HEB) traded up 0.41% on Tuesday, reaching $0.64. 225,779 shares of the company’s stock were exchanged. The company’s market cap is $16.76 million. Hemispherx BioPharma has a 52 week low of $0.39 and a 52 week high of $2.64. The stock’s 50 day moving average is $0.58 and its 200 day moving average is $0.69.
TRADEMARK VIOLATION WARNING: This report was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/2537040/hemispherx-biopharma-inc-heb-short-interest-update.html.
About Hemispherx BioPharma
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.